Regulation Panel Discussion: Scaling a Biomarker Test to Global Markets

Time: 5:25 pm
day: Track B - Day 1 pm


• Discussing the nuances in regulatory approvals and launching drug & diagnostic products in different markets (US, EU, APAC)
• The importance of China as a market and why industry should come together more to discuss streamlining infrastructure planning and data handling protection to lower costs and planning time when launching biomarker-driven drug programmes